Objective To compare the short-term efficacy and main side effects between one-week and two-week schedule of cetuximab plus chemotherapy for metastatic colorectal cancer. Methods 56 patients with metastatic colorectal cancer were enrolled, ECOG physical status 0～2, good liver and renal function, using the RECIST published in 2000 to evaluate the measurable lesions. 30 patients received oneweek schedule of cetuximab plus chemotherapy, cetuximab was administered at an initial dose of 400 mg/m~2 followed by weekly doses of 250 mg/m~2; 26 patients received two -week schedule of cetuximab plus chemotheraphy, cetuximab was administered at an initial dose of 500 mg/m~2 and the same dose was given every two weeks. The termination of the study was patients finishing 8 weeks treatment or disease progress.Results 28 patients were evaluable in one-week schedule group: CR 1, PR 7, SD 11, PD 9, RR was 28.6 %,DCR was 67.9 %. 26 patients were evaluable in two-week schedule: none of CR, PR 8, SD 9, PD 9, RR was 30.8 %, DCR was 65.4 %, and no significant difference was found(P >0.05). Grade Ⅲ-Ⅳ toxicity were rash,nausea, vomiting, neutropenia and reduction of leukemia, no significant difference was found in the two groups (P >0.05). Conclusion The therapeutic effect and safety for metastatic colorectal cancer are similar between one-week and two-week schedule of cetuximab plus chemotherapy.

OBJECTIVE:To systematically review the efficacy and safety of rosiglitazone and metformin in the treatment of type 2 diabetes,and provide evidence-based reference for the clinical treatment. METHODS:Retrieved from PubMed,Medline, EMBase,Cochrane Library,CJFD,VIP and Wanfang database,randomized controlled trials (RCT) about rosiglitazone (test group)and metformin(control group)in the treatment of type 2 diabetes. After data extract and quality evaluation,Meta-analysis was performed by using Rev Man 5.0 statistics software. RESULTS:A total of 5 RCT were included involving 636 patients. Re-sults of Meta-analysis showed the incidence of diarrhea [RR=0.23,95%CI(0.07,0.81),P=0.000] in test groupwere significantly lower than control group,the HbA1c level [MD=0.22,95%CI(0.07,0.38),P=0.004],the incidence of edema [RR=0.20,95%CI (0.05,0.57),P=0.011] in test group was significantly higher than control group,and there was no significant difference in the fast-ing blood glucose level[MD=0.27,95%CI(-0.26,0.79),P=0.32],the incidence of nausea/vomiting [RR=0.94,95%CI(0.06, 0.89),P=0.692]between 2 groups. CONCLUSIONS:Metformin is more effective than rosiglitazone in the treatment of type 2 dia-betes,however,the incidence of diarrhea should be noticed. Due to the limit of methodological quality and sample size,it remains to be further verified with more rigorously designed and long-term follow-up of large-scale RCT.

Objective To evaluate the clinical efficacy and safety of akatinol memantine in the treatment of Alzheimer's disease (AD).Methods Two hundred and forty-one patients with AD were randomly assigned to receive 10 mg of donepezil daily or 20 mg of memantine daily for 24 weeks.The primary efficacy variables were the Clinician' s Interview-Based Impression of Change Plus (CIBIC-Plus),the Alzheimer Disease Assessment Scale-cognition (ADAS-cog) and the Activities of Daily Living (ADL).The secondary efficacy variables were the Neuropsychiatric Inventory (NPI) and the Mini-Mental Status Examination (MMSE).Results Two hundred and seven patients completed the study and were evaluated at week 24.Both memantine and donepezil had significant efficacies at the end point, according to the ADAS-cog, the ADL, the NPI and the MMSE.Patients receiving memantine had a similar outcome as those receiving donepezil, according to the results of all the variables changes (CIBIC-Plus: memantine 3.4±0.8vs donepezil 3.5±0.8; ADAS-cog: memantine-4.7±5.8 vs donepezil-4.6±6.5; ADL: memantine -2.4±6.7 vs donepezil-2.2±5.3 ; NP1: memantine-5.8±9.0 vs donepezil-3.1±8.5 ; MMSE:memantine 1.7±3.1 vs donepezil 1.8±2.8, all P >0.05).The adverse events were as following: donepezil group 41.88% and memanintine group 30.58%.Conclusion The memantine as a new drug for AD, has the similar efficacy as donepezil, and it is safe.

External Guide Sequences (EGSs) represents a novel nucleic acid based gene interference approach to modulate gene expression. They are oligonucleotides that consist of a sequence complementary to a target mRNA and recruit intracellular RNase P for specific degradation of the target RNA. DNA-based EGS1386 with a size of 12 nt was chemically synthesized to target the mRNA coding for the UL49 gene of human cytomegalovirus (HCMV). The DNA-based EGS1386 molecule efficiently directed human RNase P to cleave the target mRNA sequence in vitro. A reduction of more than 50% in the levels of UL49 expression was observed in human cells treated with the DNA-based EGS1386 targeted UL49 assayed by fluorescent quantization PCR and Western blotting. This results showed that the DNA-EGS1386 can effectively guide the RNase P cut the target mRNA. Therefore, DNA-EGS can develop into a new gene silencing technology and potential of the anti-viral reagents.
Base Sequence ; Cytomegalovirus ; drug effects ; genetics ; metabolism ; Cytomegalovirus Infections ; enzymology ; virology ; DNA, Viral ; genetics ; Directed Molecular Evolution ; methods ; Gene Expression Regulation, Viral ; Humans ; Nucleic Acid Conformation ; Oligodeoxyribonucleotides ; genetics ; pharmacology ; RNA, Guide ; chemistry ; pharmacology ; RNA, Messenger ; genetics ; metabolism ; Ribonuclease P ; genetics ; metabolism ; Viral Structural Proteins ; genetics ; metabolism

Objective To investigate and analyze the reasons for the omission of adjuvant radiotherapy after breast-conserving surgery (BCS) in patients with breast cancer.Methods The clinicopathologial characteristics and socioeconomic data of 55 breast cancer patients undergoing BCS without postoperative adjuvant radiotherapy in our hospital from 2012 to 2016 were retrospectively analyzed.Results Among the 55 patients who did not receive radiotherapy,25 patients were due to low local recurrence risk,12 patients were due to economic or family reasons,12 patients were due to fear of adverse reactions of radiotherapy,and 5 patients were not recommended by primary physicians for radiotherapy.In addition,3 cases with multiple distant metastases and 3 cases with concomitant thyroid cancer didn't received radiotherapy.Conclnsions Low risk local recurrence is the main reason for the omission of adjuvant radiotherapy,followed by the fear of radiation-induced toxicity and poor financial support.Patient education and medical insurance may improve the adjuvant radiotherapy compliance.